Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor

A 94-year-old White man presented for the treatment of a recurrent cutaneous squamous cell carcinoma of the forehead. The lesion started 1 year ago and was treated initially with electrodesiccation and curettage followed by topical fluorouracil. At recurrence, the patient was offered surgery and rad...

Full description

Saved in:
Bibliographic Details
Main Authors: Sach Thakker, Jafar Al-Mondhiry
Format: Article
Language:English
Published: American College of Physicians 2024-03-01
Series:Annals of Internal Medicine: Clinical Cases
Online Access:https://www.acpjournals.org/doi/10.7326/aimcc.2023.0570
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850198014013997056
author Sach Thakker
Jafar Al-Mondhiry
author_facet Sach Thakker
Jafar Al-Mondhiry
author_sort Sach Thakker
collection DOAJ
description A 94-year-old White man presented for the treatment of a recurrent cutaneous squamous cell carcinoma of the forehead. The lesion started 1 year ago and was treated initially with electrodesiccation and curettage followed by topical fluorouracil. At recurrence, the patient was offered surgery and radiation therapy but opted for systemic therapy targeting programmed death-1 inhibition (pembrolizumab). Accelerated regression and complete resolution of the tumor was observed after the first 3 infusions with no major side effects. Immunotherapy represents a major step forward in the treatment of advanced cutaneous squamous cell carcinoma, with high efficacy and a modest side effect profile favorable for many patients.
format Article
id doaj-art-cc01a9dc6dbe44feb9b7f16b59cf767e
institution OA Journals
issn 2767-7664
language English
publishDate 2024-03-01
publisher American College of Physicians
record_format Article
series Annals of Internal Medicine: Clinical Cases
spelling doaj-art-cc01a9dc6dbe44feb9b7f16b59cf767e2025-08-20T02:12:58ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642024-03-013310.7326/aimcc.2023.0570Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 InhibitorSach Thakker0Jafar Al-Mondhiry11Georgetown University School of Medicine, Washington, DC2Inova Schar Cancer Institute, Fairfax, VirginiaA 94-year-old White man presented for the treatment of a recurrent cutaneous squamous cell carcinoma of the forehead. The lesion started 1 year ago and was treated initially with electrodesiccation and curettage followed by topical fluorouracil. At recurrence, the patient was offered surgery and radiation therapy but opted for systemic therapy targeting programmed death-1 inhibition (pembrolizumab). Accelerated regression and complete resolution of the tumor was observed after the first 3 infusions with no major side effects. Immunotherapy represents a major step forward in the treatment of advanced cutaneous squamous cell carcinoma, with high efficacy and a modest side effect profile favorable for many patients.https://www.acpjournals.org/doi/10.7326/aimcc.2023.0570
spellingShingle Sach Thakker
Jafar Al-Mondhiry
Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor
Annals of Internal Medicine: Clinical Cases
title Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor
title_full Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor
title_fullStr Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor
title_full_unstemmed Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor
title_short Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor
title_sort complete resolution of bulky cutaneous squamous cell carcinoma by programmed death 1 inhibitor
url https://www.acpjournals.org/doi/10.7326/aimcc.2023.0570
work_keys_str_mv AT sachthakker completeresolutionofbulkycutaneoussquamouscellcarcinomabyprogrammeddeath1inhibitor
AT jafaralmondhiry completeresolutionofbulkycutaneoussquamouscellcarcinomabyprogrammeddeath1inhibitor